News & Insights
Press Releases
- May 20, 2026 Acuitas Therapeutics Highlights In Vivo CAR T Cell Engineering and Ionizable Lipid Quality Attributes at the 2026 ASGCT Annual Meeting
- April 27, 2026 Acuitas Therapeutics Announces Four Scientific Presentations at the 2026 ASGCT Annual Meeting
- April 13, 2026 Acuitas Therapeutics To Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Presentations
-
May 28, 2026 LNP Technology for Infectious Disease and Cancer mRNA Vaccines
-
May 25, 2026 Optimization of ALC-315® Yields Superior Ionizable Lipids for LNP Mediated Nucleic Acid Delivery
-
May 15, 2026 Ionizable lipid impurities drive RNA-lipid adduct formation in LNPs, impacting in vivo expression (Presentation)
Page: /
Publications
- August 7, 2026 Hioe et al. (2026) “An HIV V1V2 mRNA-LNP vaccine induces strong, cross-clade functional antibody responses in mice and rhesus macaques” Journal of Immunology.
- July 6, 2026 Marchitto et al. (2026) “Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies” Nature.
- June 10, 2026 Krooss et al. (2026) “LNP-mediated base editing reduces hepatic iron overload and modifies fibrosis- and HCC-associated gene expression in HFE-related hemochromatosis mice” Journal of Hepatology.